Therapeutics News and Research

RSS

Review highlights next-generation cancer therapies targeting PIK3CA mutations

A newly published review in Genes & Diseases explores the oncogenic activation of PIK3CA in cancer and highlights emerging targeted therapies designed to improve treatment efficacy while reducing side effects.

25 Feb 2025

New insights into mTOR pathway offer hope for diabetic nephropathy treatment

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its potential as a therapeutic target.

25 Feb 2025

Novel form of life-threatening skin disease identified using innovative diagnostic platform

A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no effective treatments beyond symptom management.

24 Feb 2025

High GATA6 expression predicts improved outcomes in pancreatic cancer

This new review article highlights the crucial role of GATA6, a transcription factor, in pancreatic ductal adenocarcinoma (PDA). The article explores GATA6's dual role in cancer progression and its potential as a biomarker and treatment target.

24 Feb 2025

Study unravels the complex interplay of the UPS in cancer development and treatment

A new review published in Genes & Diseases explores the pivotal role of the ubiquitin-proteasome system (UPS) in regulating the tumor microenvironment (TME) and driving cancer progression. The study provides novel insights into how ubiquitination and deubiquitination impact tumor cells, immune responses, and potential therapeutic strategies for cancer treatment.

24 Feb 2025

Unveiling the role of FAM20C in disease and cancer treatment

A new review published in Genes & Diseases explores the multifaceted role of FAM20C, a Golgi protein kinase, in disease progression.

23 Feb 2025

Breakthrough method opens door to fluorinated oxetane drug molecules

Researchers from the National University of Singapore (NUS) have pioneered a new catalytic transformation that converts epoxides into fluorinated oxetanes, a coveted but difficult-to-make class of drug molecules that escaped synthetic preparation for years.

22 Feb 2025

New photosensitizer shows promise in treating colorectal cancer

Colorectal cancer (CRC) is a highly malignant disease that readily metastasizes to vital organs. Many strategies have been employed for clinical CRC therapy.

22 Feb 2025

Exploring the dual role of LKB1 in tumor suppression and promotion

Mutations in serine-threonine kinase 11 (STK11) and liver kinase B1 (LKB1) are associated with disease progression in Peutz-Jeghers syndrome (PJS), which can progress to cancer.

22 Feb 2025

Discovery paves way for new hepatitis B treatment

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center (MSK), Weill Cornell Medicine, and The Rockefeller University identified a vulnerability that opens the door to new treatments.

22 Feb 2025

New computational tool iDOMO improves prediction of drug synergy

Researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases.

22 Feb 2025

New human antibody shows promise for Ebola virus treatment

New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus therapeutics.

21 Feb 2025

Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.

21 Feb 2025

Characterizing the spectrum of mitochondrial DNA deletion disease syndromes

Researchers from the Mitochondrial Medicine Program at Children's Hospital of Philadelphia (CHOP) have better characterized a spectrum of what were classically considered discrete mitochondrial DNA deletion disease syndromes.

21 Feb 2025

New robotic surgery device aims to enhance precision in retinal procedures

When even the most highly trained surgeons perform procedures on the retina-one of the smallest, most delicate parts of the human body-the stakes are high.

21 Feb 2025

Boston University professor receives grant for preeclampsia drug discovery research

Wendy Kuohung, MD, associate professor of obstetrics & gynecology at Boston University Chobanian & Avedisian School of Medicine, has been awarded a two-year, Discovery Research Grant from March of Dimes.

21 Feb 2025

New 3D lung model advances respiratory medicine research

Respiratory diseases are a challenging problem to treat. Inhalable medicines are a promising solution that depend on the ability to deliver tiny particles known as aerosols to the correct location in the lungs at the correct dosage.

20 Feb 2025

Scientists uncover hidden genetic causes of congenital heart disease

Scientists at the Icahn School of Medicine at Mount Sinai and collaborators have identified novel genetic interactions that may contribute to congenital heart disease (CHD), a common birth defect.

20 Feb 2025

CPRIT awards nearly $23 million to MD Anderson for cancer research projects

The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of 20 cancer research projects to advance new breakthroughs in discovery, translational, clinical and prevention science.

20 Feb 2025

Ginger's furanodienone compound may offer new treatment for inflammatory bowel disease

An international team led by researchers at the University of Toronto has found a compound in ginger, called furanodienone (FDN), that selectively binds to and regulates a nuclear receptor involved in inflammatory bowel disease (IBD).

19 Feb 2025